$ANL News

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Jefferies Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $31

HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $20 Price Target

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors

Adlai Nortye: AN9025 Still Needs Human Validation

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, A Pan-RAS(ON) Inhibitor

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Cantor Fitzgerald Initiates Coverage On Adlai Nortye with Overweight Rating

Oppenheimer Initiates Coverage On Adlai Nortye with Outperform Rating, Announces Price Target of $32

Jones Trading Initiates Coverage On Adlai Nortye with Buy Rating, Announces Price Target of $22

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?